8-K: Rallybio to Merge with Candid, Securing $505M Financing

Rallybio Corporation will merge with clinical-stage Candid Therapeutics, Inc., with Candid's equityholders taking a majority stake and a concurrent $505.5 million financing to fund operations through 2030.

Summary

• Rallybio Corporation (RLYB) has entered into a definitive merger agreement with Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on T-cell engager (TCE) therapeutics for autoimmune diseases.
• Upon completion, Candid will become a wholly-owned subsidiary of Rallybio, and the combined company will operate as Candid Therapeutics, Inc., trading on Nasdaq under the ticker symbol CDRX.
• Pre-merger Candid equityholders, including new investors, are expected to own approximately 96.35% of the combined company, while pre-merger Rallybio equityholders will own approximately 3.65%.
• A concurrent, oversubscribed private financing of over $505.5 million in gross proceeds has been committed by a syndicate of leading healthcare institutional investors and mutual funds.
• The combined company's cash balance at closing is projected to be approximately $700 million, expected to fund operations through 2030.
• Existing Rallybio stockholders will receive Contingent Value Rights (CVRs) entitling them to a portion of cash proceeds from the sale of Rallybio's pre-merger assets, including interests in REV102 and other legacy assets.
• The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in mid-2026.
• The combined company will be led by Dr. Ken Song, Candid's Chairman, President, and CEO, with Rallybio's current executive officers and directors expected to resign.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, particularly for Candid's pipeline and the combined entity's financial stability. The substantial, oversubscribed financing and the promising clinical data for Candid's TCE programs suggest significant future value creation, despite the substantial dilution for existing Rallybio shareholders.

Positives

• Secured an oversubscribed and upsized private financing of over $505.5 million, providing a strong financial foundation.
• Expected pro-forma cash of approximately $700 million at closing is anticipated to fund operations through 2030.
• Candid brings a leading and diversified pipeline of T-cell engager (TCE) therapeutics for autoimmune diseases, with ongoing clinical studies in over 10 indications.
• Cizutamig, a BCMA TCE, has shown favorable tolerability with low rates of mild cytokine release syndrome (CRS) and emerging clinical data suggesting deeper therapeutic activity with less frequent dosing than anti-FcRn drugs.
• Global Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease (ILD) are planned to initiate in 2026.
• CND261, a CD20 TCE, has been dosed in over 100 patients across oncology and autoimmune indications with low CRS rates and early evidence of deep tissue B-cell depletion.
• CND319, a dual-targeting CD19 and CD20 TCE, has demonstrated a promising therapeutic index profile in non-human primate studies, with first-in-human studies planned for mid-2026.
• The combined company will be led by an experienced management team with deep expertise in autoimmune drug development and TCE biology.
• The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Negatives

• Significant dilution for pre-merger Rallybio equityholders, who are expected to own only approximately 3.65% of the combined company.
• Rallybio's current executive officers and directors are expected to resign, indicating a complete change in leadership and strategic direction for the public entity.
• The value of the Contingent Value Rights (CVRs) for Rallybio's legacy assets is uncertain, with no assurance that holders will receive any payments.

Risks

• Conditions to closing the proposed Merger may not be satisfied, including failure to obtain timely stockholder approval.
• Uncertainties exist regarding the timing of the consummation of the proposed Merger.
• Rallybio's ability to manage operating expenses and merger-related expenses pending closing is a risk.
• Failure or delay in obtaining required governmental or regulatory approvals could impact the merger.
• Adjustments to the exchange ratio could result in Rallybio's stockholders owning more or less of the combined company than currently anticipated.
• Risks related to the market price of Rallybio Common Stock relative to the value suggested by the exchange ratio.
• Unexpected costs, charges, or expenses may arise from the proposed transaction.
• Potential adverse reactions or changes to business relationships could result from the announcement or completion of the Merger.
• Uncertainties are associated with Candid's product candidates and platform technologies, including risks in clinical development and regulatory approval, and potential delays in trials.
• The combined company may be unable to obtain sufficient additional capital to advance product candidates and preclinical programs.
• Uncertainties exist in obtaining successful clinical results for product candidates and unexpected costs may arise.
• There is a risk of failure to realize value from product candidates and preclinical programs due to inherent difficulties in bringing them to market.
• Risks are associated with the possible failure to realize certain anticipated benefits of the proposed Merger.
• The concurrent financing may not be consummated.
• The possibility exists that holders of CVRs may never receive any proceeds from the disposition of legacy assets.

Future Outlook

The combined company, Candid Therapeutics, Inc., expects to fund operations through 2030, supporting the advancement of its diversified pipeline of T-cell engager (TCE) programs through multiple clinical milestones. This includes the initiation and clinical readouts of Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease (ILD) secondary to rheumatological diseases in 2026, and first-in-human studies for CND319 (CD19/CD20 TCE) in mid-2026 and CND460 (BCMA/CD19 TCE) in 1H 2027.

Management Comments

• Dr. Ken Song, Chairman, President and Chief Executive Officer of Candid Therapeutics, stated: 'This transaction marks an exciting moment for Candid as we lead the development of TCEs for patients with autoimmune diseases. By combining with Rallybio and securing over $505 million in new financing from a distinguished group of healthcare investors, we have the resources to advance what we view as a transformative therapeutic modality. With Phase 2 studies planned for cizutamig in 2026 and a rich pipeline of next-generation TCE programs, we will continue to push forward this new drug class.'
• Dr. Stephen Uden, Co-Founder and Chief Executive Officer of Rallybio, commented: 'We are pleased to announce this transaction, which we believe represents a compelling opportunity for Rallybio stockholders to participate in the future value creation of a well-capitalized, clinical-stage company with a differentiated and broad portfolio of TCE drug candidates. Candids clinical data in myasthenia gravis and across its autoimmune pipeline, combined with the strong endorsement of leading healthcare investors further substantiates the merit of this transaction.'

Industry Context

StockSavvy.ai notes that this reverse merger and significant financing highlight a growing trend in the biotechnology sector where private, well-funded companies with promising pipelines are leveraging public shells to access capital markets and accelerate development. The focus on T-cell engager (TCE) therapeutics for autoimmune diseases positions the combined entity in a high-potential, evolving therapeutic area, aiming to replicate the success seen with CAR-T therapies in oncology by offering scalable, outpatient-friendly B-cell and plasma cell depletion. The substantial capital raise from leading healthcare investors signals strong market confidence in Candid's platform and pipeline, particularly its BCMA, CD19, and CD20 TCE programs, which could become competitive alternatives to existing treatments like anti-FcRn drugs and even CAR-T in autoimmune indications.

Comparison to Industry Standards

• Candid's cizutamig (BCMA TCE) is positioned as a potential firstand best-in-class for autoimmune diseases, with clinical data suggesting deeper therapeutic activity and less frequent dosing compared to the anti-FcRn drug class, which includes approved therapies like Vyvgart (efgartigimod) for myasthenia gravis.
• The filing highlights that BCMA targeting (as seen with CAR-T) has dramatically reduced autoreactome in cancer patients, suggesting a similar potential for maximal clinical efficacy in autoantibody-driven autoimmune diseases, potentially surpassing CD19 (CAR-T) or CD20 (Rituximab) approaches in certain contexts.
• Cizutamig's in vitro data show reduced cytokine release while maintaining B-cell cytotoxicity compared to other BCMA TCEs, and clinical data in multiple myeloma indicate an improved CRS profile with comparable efficacy to other BCMA TCEs like Teclistamab (Janssen Biotech).
• CND261 (CD20 TCE) also demonstrates an improved CRS profile and comparable efficacy to other CD20 TCEs in Non-Hodgkin's Lymphoma, such as those from Genmab/AbbVie (epcoritamab) or Roche (glofitamab), based on the filing's comparisons.
• The strategy of 'immune reset' (full B/plasma cell depletion for drug-free remission) and 'immune dimming' (partial depletion for superior efficacy with minimal infection risk) offers a differentiated approach compared to standard-of-care polypharmacy or existing biologics like anti-FcRn or interleukin inhibitors.

Management Changes

Corporate Governance

Related Party Transactions

• Amendments to employment agreements for Stephen Uden, Jonathan Lieber, and Steven Ryder clarify that the Merger will constitute a change in control for purposes of their respective employment agreements, potentially triggering certain payment and benefits.

Stakeholder Impact

• **Shareholders (Rallybio pre-merger):** Will experience significant dilution, owning approximately 3.65% of the combined company. They will receive Contingent Value Rights (CVRs) for legacy assets, offering potential but uncertain future cash proceeds.
• **Shareholders (Candid pre-merger & new investors):** Will own approximately 96.35% of the combined company, gaining access to public markets and benefiting from a substantial capital infusion to advance Candid's pipeline.
• **Employees (Rallybio):** Current executive officers and directors are expected to resign, indicating a change in leadership. The impact on other employees is not explicitly detailed but a wind-down of Rallybio's preclinical, CMC, and clinical activities is planned.
• **Employees (Candid):** Candid's management team will lead the combined company, suggesting continuity and growth opportunities. New equity incentive plans are being established for employees.
• **Customers/Patients:** The merger aims to accelerate the development of T-cell engager therapeutics for autoimmune diseases, potentially bringing new treatment options to patients with high unmet medical needs.
• **Suppliers/Creditors:** Rallybio's existing contracts and liabilities will be managed, with certain agreements to be terminated or wound down. The combined company's strong cash position should provide stability for ongoing operations.

Next Steps

• Rallybio will prepare and file a registration statement on Form S-4, including a proxy statement and prospectus, with the SEC.
• Rallybio will seek stockholder approval for the issuance of shares, a reverse stock split, the name change to Candid Therapeutics, Inc., an increase in authorized shares, and new equity incentive plans.
• Candid will seek requisite stockholder approval for the adoption of the Merger Agreement and related transactions.
• The companies will work to satisfy other closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• The closing of the Merger is expected in mid-2026.
• The combined company will initiate global Phase 2 studies for cizutamig in myasthenia gravis and interstitial lung disease in 2026.
• First-in-human studies for CND319 (CD19/CD20 TCE) are planned for mid-2026.
• First-in-human studies for CND460 (BCMA/CD19 TCE) are planned for 1H 2027.
• Rallybio will use commercially reasonable efforts to effect the disposition of its Legacy Assets for CVR holders for one year after the Closing Date.

Key Dates

Recommendation

The merger with Candid Therapeutics, coupled with a substantial $505.5 million financing, provides Rallybio's public shell with a promising clinical-stage pipeline in T-cell engagers for autoimmune diseases and a strong cash runway through 2030. This is a transformative event, effectively a reverse merger where Candid's assets and management take control. While the significant dilution for existing Rallybio shareholders is a negative, the CVRs offer some potential upside from legacy assets. The new entity's focus on a high-potential therapeutic area with encouraging early clinical data warrants attention. However, the inherent risks of clinical development, regulatory approvals, and the speculative nature of CVRs suggest a 'hold' recommendation for seasoned investors, allowing time to assess the execution of Candid's pipeline and the realization of value from the CVRs. A 'buy' would be premature given the complete shift in company identity and the early stage of some programs, while a 'sell' would ignore the significant capital infusion and promising new direction.

Keywords

Merger, Biotechnology, Autoimmune Diseases, T-cell Engager, BCMA TCE, CD20 TCE, CD19 TCE, Clinical Stage, Private Financing, Nasdaq Listing, Contingent Value Rights, Myasthenia Gravis, Interstitial Lung Disease, Drug Development, Biopharma